Search clinical trials for: Androxal

Total 24 results

Baylor College of Medicine

Withdrawn

Androxal in Male Infertility

Infertility

United States
Repros Therapeutics Inc.

Completed

Comparison of Two Formulations of Androxal

Bioequivalence

United States
Repros Therapeutics Inc.

Completed

The Effect on Androxal Versus Androgel on Morning Testosterone in Men With Secondary Hypogonadism (Low Testosterone)

Secondary Hypogonadism

United States
Repros Therapeutics Inc.

Completed

To Evaluate Sperm Parameters in Men With Secondary Hypogonadism Previously Treated With Topical Testosterone

Secondary Hypogonadism

United States
Repros Therapeutics Inc.

Completed

Phase III Study to Evaluate Morning Testosterone Normalization in Overweight Men With Secondary Hypogonadism

Secondary Hypogonadism

United States
Repros Therapeutics Inc.

Completed

Phase III Study to Evaluated Morning Testosterone Normalization in Men With Secondary Hypogonadism

Secondary Hypogonadism

United States
Repros Therapeutics Inc.
Celerion

Completed

An Open-Label, Single-Dose Study to Assess the Absorption, Metabolism, Excretion, and Mass Balance of Radiolabeled Androxal in Healthy Male Subjects After Oral Administration

Secondary Hypogonadism

United States
Repros Therapeutics Inc.

Completed

Assessment of the Effects of Enclomiphene Citrate on Bone Mineral Density in Men With Secondary Hypogonadism

Effect of Treatment on Bone Mineral Density

United States
Repros Therapeutics Inc.

Completed

A Randomized, Double Blind, Placebo-Controlled, Multi-Center Phase III Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Testosterone and Sperm Concentration Following Treatment With 12.5 mg or 25 mg Androxal or AndroGel 1.62%

Secondary Hypogonadism

United States
Repros Therapeutics Inc.

Completed

A Randomized, Double Blind, Placebo-Controlled, Multi-Center Phase III Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Testosterone and Sperm Concentration Following Treatment With 12.5 mg or 25 mg Androxal or AndroGel 1.62%

Secondary Hypogonadism

United States
Repros Therapeutics Inc.

Completed

An Open-Label Study to Evaluate the Effect of Age Upon the Pharmacokinetics of Androxal

Pharmacokinetics

United States
Repros Therapeutics Inc.

Completed

A Dose Escalating Study to Determine the Tolerability and PK of a Single Dose of Androxal

Pharmacokinetics | Tolerability

United States
Repros Therapeutics Inc.

Completed

Evaluation of Pharmacokinetic and Safety Profile of Androxal in Male Subjects With Impaired Renal Function

Secondary Hypogonadism

United States
Repros Therapeutics Inc.

Completed

Study to Evaluate the Effect of Food Upon the Pharmacokinetics of Androxal

Normal Volunteers
Repros Therapeutics Inc.

Completed

Assessment of Drug-Drug Interactions of Androxal With Cytochrome P450 Isoenyzmes in Healthy Males

Drug-drug Interaction

United States
Repros Therapeutics Inc.

Completed

Normalization of Morning Testosterone Levels in Men With Secondary Hypogonadism

Secondary Hypogonadism

United States
Repros Therapeutics Inc.

Completed

Safety Study of Enclomiphene Citrate in the Treatment of Men With Secondary Hypogonadism

Secondary Hypogonadism

United States
Repros Therapeutics Inc.

Completed

Study to Evaluate the Efficacy of Androxal in Controlling Blood Glucose in Men With Type-2 Diabetes Mellitus

Type 2 Diabetes Mellitus | Secondary Hypogonadism

United States
Repros Therapeutics Inc.

Completed

Study to Evaluate the Safety and Efficacy of Androxal Treatment in Men With Secondary Hypogonadism (ZA-003Ext)

Secondary Hypogonadism

United States
Repros Therapeutics Inc.

Completed

A Thorough QT/QTc Study to Assess the Effects of Androxal in Healthy Male Subjects

Healthy
Repros Therapeutics Inc.

Completed

An Extension Study of Enclomiphene Citrate in the Treatment of Men With Secondary Hypogonadism

Secondary Hypogonadism
Repros Therapeutics Inc.

Completed

Evaluation of the Pharmacokinetics and Safety of Androxal in Male Subjects With Impaired Hepatic Function

Secondary Hypogonadism

United States
Repros Therapeutics Inc.

Completed

A One Year Open Label Study for the Treatment of Hypogonadism (Low Testosterone) in Men Who Have Completed ZA-203

Hypogonadism | Low Testosterone

United States
Repros Therapeutics Inc.

Completed

Study to Evaluate the Safety and Efficacy of Androxal™ Treatment in Men With Secondary Hypogonadism

Secondary Hypogonadism

United States

3

Subscribe